Skip to content
跳至主要內容
SPY
···
QQQ
···
IWM
···
DIA
···
AAPL
···
MSFT
···
NVDA
···
GOOGL
···
AMZN
···
META
···
TSLA
···
BRK.B
···
JPM
···
GLD
···
TLT
···
BTC
···
ETH
···
VIXY
···
UUP
···
USO
···
SPY
···
QQQ
···
IWM
···
DIA
···
AAPL
···
MSFT
···
NVDA
···
GOOGL
···
AMZN
···
META
···
TSLA
···
BRK.B
···
JPM
···
GLD
···
TLT
···
BTC
···
ETH
···
VIXY
···
UUP
···
USO
···
Stock detail
Loading institutional stock data...
← BACK TO COCKPIT
ALL TICKERS →
OPTIONS CHAIN →
MNPR
Monopar Therapeutics Inc.
NASDAQCM
Biotechnology
United States
$117.86
▼
-0.69 (-0.59%)
OPEN
—
OPEN
$117.85
HIGH
$119.00
LOW
$116.21
PREV CLOSE
$118.55
VOLUME
50.3K
0.23x avg
MARKET CAP
$791.1M
DAY RANGE
$116.21
$119.00
P/E (TTM)
—
Fwd -59.5
EPS (TTM)
-2.21
DIV YIELD
—
52W HIGH
$124.82
-5.6%
52W LOW
$38.66
+204.8%
BETA
1.51
vs S&P 500
DES
FA
GP
OPT
HLDR
EARN
CMP
COMPARE
ASK DESK
PRE-MARKET
$118.01
-0.54
(-0.46%)
LAST SURPRISE
—
—
NEXT EARNINGS
—
—
CATALYST
No fresh catalyst
—
ANALYST
—
—
SHORT INT
—
—
OPTIONS IV
—
—
MNPR
$117.86
▼
-0.59%
Chart
Valuation
Financials
Peers
News
MNPR · K 線技術分析（即時、可互動）
basic
pro
快速分析（約 90–120 秒）
Loading K-line chart…
按上方「快速分析」，研究台會以這張 K 線為起點跑一輪快速回答：三個分析師視角（總經、基本面、技術面）加交易計畫與風險統計，約 90–120 秒。想要五隊深度研究與機構級報告，請在研究台把模式切到「深度」。
1-YEAR PRICE
One-Year Trajectory
RISK-ON
253 BARS · +203.4% YOY
1-year price chart. Started at 38.84, currently 117.86, up 203.4 percent. Range 38.84 to 123.84 over 253 data points.
2025-09-04
$38.84 → $117.86 (+203.4%)
2026-09-04
§ Valuation
Loading § Valuation
§ Multi-Year Financials
Loading § Multi-Year Financials
§ Peers
Loading § Peers
§ Recent News
Loading § Recent News
EDITORIAL · NOT INVESTMENT ADVICE.
Data sources: Finnhub (quote / profile / news / peers) + Yahoo (stats) + SEC EDGAR XBRL (financials + DCF). All values cached for 5 minutes via ISR.
VALUATION
Deterministic Valuation (SEC EDGAR + Finnhub)
—
NO DCF
DCF Fair Value
—
DCF vs Spot
—
Comps Fair Value
$51.62
WACC Used
+7.0%
Terminal g
+3.5%
Verdict: strong-sell
· peers $51.62 (-56.2%)
Peers:
ACHV
FDMT
NVCT
CTMX
CBIO
AURA
NGNE
ASMB PE29
⚠ DCF skipped: missing FCF or shares data from SEC EDGAR. Often the case for non-US issuers.
FINANCIALS
Multi-Year Financials (SEC XBRL)
—
4 FY · NO YOY
FY
Revenue
Net Income
OCF
FCF
Assets
2025-12
$0.00
-$13.7M
-$12.2M
—
$140.7M
2024-12
$0.00
-$15.6M
-$6.4M
—
$60.3M
2023-12
$0.00
-$8.4M
-$7.9M
—
$7.3M
2019-12
$0.00
—
—
—
—
PEERS
Sector & Industry Peers
CALM
10 PEERS · FINNHUB
ACHV
FDMT
NVCT
CTMX
CBIO
AURA
NGNE
ASMB
MPLT
950160.KQ
NEWS
Recent News (past 14 days)
CALM
10 HEADLINES · LAST 14 DAYS
Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026
GlobeNewswire · 2026-08-19
Sector Update: Healthcare Stocks Softer Late Afternoon
MT Newswires · 2026-08-13
Monopar Therapeutics Shares Drop After Downgrade From Cantor Fitzgerald
MT Newswires · 2026-08-13
Cantor Fitzgerald Downgrades Monopar Therapeutics to Neutral From Overweight, Adjusts PT to $119 From $109
MT Newswires · 2026-08-13
Monopar Therapeutics' Q2 Net Loss Widens
MT Newswires · 2026-08-12
Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates
GlobeNewswire · 2026-08-12
Monopar Therapeutics Begins Rolling Application for ALXN1840 in Wilson Disease
MT Newswires · 2026-07-22
Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease
GlobeNewswire · 2026-07-22